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ABSTRACT 
The aim of the present work is to develop sustained release parenteral drug delivery system of contraceptive drug i., e medroxyprogesterone 
acetate. The formulation was prepared by sterile combining of API and excipient powders by rapid stirring method. Different excipients used in 
the formulation are PEG 3350, Poloxamer -188, Polysorbate-80, Benzyl alcohol and Sodium chloride. The prepared parenteral suspension was 
evaluated for all official parameters like sedimentation volume, measurement of zeta potential, pH, viscosity, osmolality, dissolution, assay, 
particle size determination, and stability studies. The dissolution profile was found to be more when compared with the innovator formulation. 
Stability studies were also conducted at 25ºC / 60% RH and 40ºC / 75% RH conditions up to 3M.All the parameters evaluated are within the 
specified limits. 
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INTRODUCTION                                                                                                                                      
The parenteral route is the most preeminent and common 
form of drug delivery system. This system generally avoids 
the drug related problems which were associated with the 
oral route are acid degradation, hepatic metabolism (first 
pass effect), enzymatic action in the intestine, unpredictable 
pharmacokinetic parameters (solubility, absorption, 
distribution etc..,). Site specific drug delivery can also be 
achieved by this route1.  
To overcome the loopholes various approaches like 
microemulsions2, liposomes, solid dispersion techniques, 
cubosomes and complexation with cyclodextrins are 
adopted. Though there reasonable success has been achieved 
employing these techniques but still some of the draw backs 
were there such as poor stability, low drug loading capacity, 
increased toxicity, complex manufacturing method3. 
Depot systems 
A depot is an injection, either administered intramuscularly 
or subcutaneously which usually deposits the drug at the site 
of injection as a mass, from which it gets absorbed and 
distributed to the tissue which surrounds it. This system 
usually releases the active compound in a consistent manner 
over a long period. The main advantage of long-acting depot 
injection includes decreased dosing frequency which in turns 
increases the patient compliance; more consistent serum 
concentration can be gained4.                                    
Parenteral suspensions are thermodynamically unstable 
heterogeneous systems in which the insoluble drug particles 
are dispersed or suspended in the dispersion medium (such 
as aqueous or non-aqueous vehicles). Particle size should be 
less than 5 μm5. Medroxy progesterone structurally 
resembles progesterone and it is widely used as 
contraceptive or hormone replacement therapy6.  The 
overall aim of the present work was to formulate the 
parenteral depot suspension and illustrate the particle size, 
pH, in- vitro drug release profile and stability parameters 
with that of innovator product.  
MATERIALS AND METHODS 
Medroxy progesterone acetate was obtained from Crystal 
pharma as a gift sample. Polyethylene glycol 3350 was 
purchased from Sigma Aldrich, USA. Polysorbaten80, 
poloxamer-188, benzyl alcohol, sodium chloride and sodium 
hydroxide were obtained from Merck chemicals Ltd., 
Mumbai. All other chemicals and reagents used were of 
analytical reagent (AR) grade. 
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Preformulation studies7 
Preformulation is the study that yields necessary 
information related to physicochemical properties of drug 
candidate in order to develop safe, effective and stable 
dosage form. This study includes 
 Physical characterization of API 
 Solubility of API 
 Drug-excipient compatibility study 
Preparation of aqueous suspension 
Aqueous suspension of medroxy progesterone acetate was 
prepared by rapid stirring method. Accurately weighed 
quantity of PEG-3350, poloxamer 188, Polysorbate 80, 
benzyl alcohol and sodium chloride was dissolved in Milli-Q 
water by continuous stirring. The API was added during 
stirring condition, at least for 45 minutes8. The formulation 
design for medroxy progesterone acetate suspension is 
represented (Table No. 1). 
 
 
Table 1: Formulation design of Medroxy progesterone acetate injectable suspension 
S.No Name of the ingredients  
(mg/mL) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1. 
 
Medroxy progesterone  
Acetate 
150 150 150 150 150 150 150 150 150 
2. Polyethylene glycol 3350 27.1 26.9 28.5 - - - 28.1 27.7 26.9 
3. Poloxomer 188 - - - 1.0 1.50 2.0 0.80 1.20 2.0 
4. Polysorbate 80 2.41 2.41 2.41 2.41 2.41 2.41 2.41 2.41 2.41 
5. Sodium chloride 8.68 8.68 8.68 8.68 8.68 8.68 8.68 8.68 8.68 
6. Benzyl alcohol 4.45 7.10 8.88 5.6 6.90 9.16 7.5 6.80 8.88 
7. Sodium hydroxide (0.1N) q.s q.s q.s q.s q.s q.s q.s q.s q.s 
8. Hydrochloric acid (0.1N) q.s q.s q.s q.s q.s q.s q.s q.s q.s 
9. Water for injection q.s q.s q.s q.s q.s q.s q.s q.s q.s 
 
In-vitro Dissolution studies 
In-vitro dissolution test was carried out by using USP type-IV 
apparatus (Flow through cell)9. 900 mL of pH 7.4 phosphate 
buffer and 0.50 % SLS was used as dissolution medium. 
Basket was rotated at 50 rpm and temperature was 
maintained at 37 ± 0.5ºC. Sampling was done at regular 
intervals and they are analysed by HPLC.  
Physical characterization of suspension 
 Particle size and zeta potential 
 pH 
 Osmolality 
 Viscosity  
RESULTS AND DISCUSSION 
Table 2: Physical characterization of API 
 
X-Ray diffraction study 
Sharp peaks were observed in the X-Ray diffractogram 
indicates crystalline nature of API.
 
 
Figure 1: XRD of Medroxy progesterone acetate 
S.No Description Results 
1. Colour White  
2. Appearance Crystalline powder 
3. Taste Bitter 
4. odor Odorless 
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Table 3: Solubility of API in different media 
Solvent system Solubility (mg/mL) 
Purified water 0.0033 
0.1 N Hcl 0.0003 
pH 4.5 acetate buffer 0.0004 
pH 6.8 phosphate buffer 0.0002 
pH 7.4 phosphate buffer 0.0014 
Water + 0.5 % SLS 0.355 
0.1 N Hcl + 0.5 % SLS 0.352 
pH 4.5 acetate buffer + 0.5 % SLS 0.383 
pH 6.8 phosphate buffer + 0.5 % SLS 0.329 
pH 7.4 phosphate buffer + 0.5 % SLS 0.449 
 
Drug-Excipient compatibility studies by FTIR                                                                                           
FTIR method was adopted to study the compatibility with 
drug and excipients. Medroxy progesterone acetate shows 
characteristics absorption bands at 3424.31cm-1 for O-H, 
2947.26cm-1 for C-H stretching, 1731.79cm-1 for C=O 
stretching and 1410.27cm-1C=C bending. There were no 
extra peaks observed in the spectrum when API in 
combination with excipient. A figure 1, 2 & 3 represents the 
compatibility between drug and the excipients mixture.
 
 
Figure 2: FTIR Spectrum of pure API  
 
 
Figure 3: FTIR Spectrum of medroxy progesterone acetate with PEG 3350 
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Figure 4: FTIR Spectrum of medroxy progesterone acetate with Poloxamer-188 
 
Assay                                                                                                                                                                                
The assay percentage of innovator and optimized 
formulation was 100.2±0.5 and 99.8±0.69 respectively. 
Assay was within the limit and matches with the innovator.      
Dissolution studies                                                                                                                                                
The drug release profiles are obtained for the innovator and 
different formulations F1, F2, F3, F4, F5, F6, F7, F8, and F9. 
Cumulative % drug release of Optimized formulation F9 0, 
41±0.79, 67±1.52, 73±0.99, 83±0.75, 89±1.13, 95±0.98, 
101±0.69 respectively. The innovator shows the drug release 
0, 43±0.91, 65±0.97, 72±0.45, 81±0.79, 88±0.98, 93±1, 
99±1.36 respectively. Among all formulations, F9 trial shows 
the increased drug release pattern than innovator.                                                 
                          
 
Table 4: Drug content 
Test Assay (96%-103% USP) 
RLD 100.2±0.51 
F1 98.5±1.02 
F2 100.9±0.98 
F3 98.7±0.59 
F4 101.5±0.12 
F5  97.9±0.85 
F6 95.9±1.05 
F7 97.8±0.39 
F8 98.1±0.78 
F9 99.8±0.69 
             Mean±standard deviation (n=3)
 
 
Table 5: Cumulative Percentage drug release of profiles 
Trials Time (hrs) 
0 1 2 3 4 6 8 12 
F1 0 39±0.5 58±0.63 67±0.20 79±1.29 87±0.91 92±1.23 96±1.49 
F2 0 48±0.21 66±0.82 72±0.85 80±2.15 84±0.67 91±0.87 97±1.54 
F3 0 29±0.82 49±0.71 65±1.09 71±1.1 79±0.98 87±1.25 93±1.49 
F4 0 52±1.14 63±1.49 71±2.1 80±0.79 87±1 91±1.53 96±1.65 
F5 0 35±0.75 51±1.13 62±0.98 71±0.83 83±0.8 89±0.86 93±0.79 
F6 0 27±1.05 46±0.99 59±1.45 71±0.29 87±1.23 95±2.7 98±1.13 
F7 0 50±0.91 61±0.84 73±1.25 79±0.87 86±1.4 88±1.11 95±2.1 
F8 0 32±0.85 56±1 69±1.05 75±1.15 87±1.21 90±1.98 94±0.94 
F9 0 41±0.79 67±1.52 73±0.99 83±0.75 89±1.13 95±0.98 101±0.69 
RLD 0 43±0.91 65±0.97 72±0.45 81±0.79 88±0.98 93±1 99±1.36 
         Note: All the values are expressed as mean± SD, n=3                                                                                                                          
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Figure 5: Cumulative % drug release of formulations F1-F8 and RLD 
Table 6:  Physical characterization 
Trials Size      (nm) Zeta potential 
(mV) 
pH  
(3.0 -7.0) 
Osmolality 
(mOsmol/kg)  
(350-410) 
Viscosity (cps)        
(6.0-9.0) 
F1 1243±11.47 -33.7±0.49 5.67 375 6.15 
F2 1190±32.7 -21.9±3.14 6.12 367 6.19 
F3 1210±21.18 -28.5±2.89 6.67 364 6.23 
F4 1240±19.8 -19.8±4.1 6.49 376 6.12 
F5 1160±45.1 -31.8±0.56 5.97 361 6.51 
F6 1290±12.5 -29.7±2.47 6.21 374 6.37 
F7 1310±5.14 -34.2±0.31 6.60 361 6.64 
F8 1180±19.2 -25.9±2.73 6.01 359 6.29 
F9 1105±17.94 -38.1±0.21 6.80 381 6.95 
RLD 1132±7.8 -35.4±0.64 6.78 379 6.92 
               Mean±standard deviation (n=3) 
Table 7: Sedimentation study analysis 
Time 
(hrs) 
F9 RLD 
 F=Vs/Vi  F=Vs/Vi 
1 1.00 1.00 
2 1.00 1.00 
4 0.99 0.98 
8 0.99 0.95 
24 0.97 0.91 
48 0.94 0.89 
72 0.90 0.89 
96 0.90 0.89 
120 0.90 0.89 
Note: Vs - Volume of sediment in mL, Vi – Initial volume & F – Sedimentation volume 
Table 8: 3M stability data of optimized formulation F9 
Formulation  F9 F9 RLD RLD 
Stability 
conditions 
25ºC / 60% RH 40ºC / 75% RH 25ºC / 60% RH 40ºC / 75% RH 
Drug content 100.1±0.6 98.8±1.23 99.8±0.69 98.4±1.07 
pH 6.79 6.76 6.77 6.74 
Osmolality 381 379 378 376 
Viscosity 6.94 6.89 6.91 6.88 
Dissolution  101.17±0.58 100.8±0.6 98.87±1.63 98.28±1.94 
Particle size (nm) 1112±10.58 1125±7.2 1145±5.89 1175±4.17 
 
Report: 
There were no marked changes observed in the 3M stability 
of optimized formulation F9 and innovator at 25ºC / 60% RH 
and 40ºC / 75% RH conditions. It indicates that optimized 
formulation F9 shows good stability like that of innovator. 
0 
20 
40 
60 
80 
100 
120 
0 2 4 6 8 10 12 14 
cu
m
u
la
ti
ve
 %
 d
ru
g 
re
le
as
e
 
Time (hrs) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 RLD 
 Sunitha Reddy et al                                                                                           Journal of Drug Delivery & Therapeutics. 2018; 8(6-s):298-303 
ISSN: 2250-1177                                                                                  [303]                                                                                 CODEN (USA): JDDTAO 
CONCLUSION                                                                                                                                           
The goal of the investigation was to develop a sustained 
release parenteral drug delivery system of contraceptive 
drug i., e medroxy progesterone acetate which was 
administered intramuscularly. Drug excipient compatibility 
was performed and the spectrums show compatibility. The 
formulation was optimized and evaluated for the parameters 
of parenteral preparations. The dissolution profile of 
optimized was more when compared with the innovator 
formulation.3M stability data at 25ºC / 60% RH and 40ºC / 
75% RH conditions generated and it shows good stability. 
Hence, this product was developed to get increased 
compliance with decreasing the dosing frequency. A stable 
pharmaceutically equivalent product was developed. 
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